I must say, I have previously been critical of RAC marketing to retail investors but today's announcement is really impressive.
In this announcement management have clearly illustrated Zantrene's massive potential. Not only cardio-protective when used in conjunction with SOC chemotherapeutics, but increase the efficacy of killing breast cancer cells.
If as a retail investor you can't understand how these results are a huge step forward towards a transaction for RAC then I don't know what will help.
Well done
Ann: Breakthrough Zantrene Heart Protection Discovery, page-114
-
- There are more pages in this discussion • 253 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
